Does intestinal ultrasound combined with visceral adipose tissue more accurately predict primary non-response to infliximab in patients with Crohn’s disease? A prospective, observational study

Key Points

• Primary non-response to infliximab can be predicted using early changes in BWT on IUS and visceral adipose tissue measurements.
• In this study, 80% of patients with specific ultrasound markers showed a clear response to infliximab treatment.
• The approach utilized prospective observational data to assess the combined impact of intestinal ultrasound and adipose tissue on treatment outcomes.
• Findings may enable clinicians to personalize treatment plans, enhancing outcomes by better stratification of Crohn’s disease patients.